NextCure Inc 2024年度报告

Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d)of the Act.Yes☐No☒ Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)has been subject to such filing requirements forthe past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” inRule12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Emerginggrowthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport. Yes☐No☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ The aggregate market value of the registrant’s common stock held by non-affiliates as of June 28, 2024, the last business day of the registrant’s most recently completedsecond fiscal quarter, was approximately $43.6million, as computed by reference to the closing price of the common stock on the Nasdaq Global Select Market on thatdate. As of March 3, 2025, the registrant had28,006,684shares of common stock, par value $0.001 per share, issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days afterDecember 31, 2024, are incorporated by reference into Part III of this Report. NextCure, Inc.Form 10-KFor the Year Ended December 31, 2024 TABLE OF CONTENTS Page PARTIItem1 Business6Item1ARisk Factors25Item1B Unresolved Staff Comments70Item 1CCybersecurity70Item2Properties70Item3Legal Proceedings71Item4Mine Safety Disclosures71 PARTIIItem5Market for Registrant’s Common Equity, Related Stockholder Matters, and IssuerPurchases of Equity Securities71Item6Selected Financial Data71Item7Management’s Discussion and Analysis of Financial Condition and Results ofOperations71Item7AQuantitative and Qualitative Disclosures About Market Risk78Item8Financial Statements and Supplementary Data79Item9Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure103Item9AControls and Procedures103Item9B Other Information103Item9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections103 PARTIII Item10 Directors, Executive Officers, and Corporate Governance103Item11 Executive Compensation104Item12 Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters104Item13 Certain Relationships and Related Transactions and Director Independence104Item14 Principal Accounting Fees and Services104 PARTIVItem15 Exhibits, Financial Statement Schedules104Item16 Form10-K Summary108SIGNATURES109 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains forward-looking statements, including with respect to ourplans, objectives and expectations for our business, operations and financial performance andcondition. Any statements contained herein that are not statements of historical facts may be deemedto be forward-looking statements. The forward-looking statements are contained principally in thesections entitled “Business,” “Risk Factors” and